Five medications have been approved for the management of obesity, but data on comparative effectiveness are limited.
(Body mass index is calculated as weight in kilograms divided by height in meters squared.) However, there is a paucity of randomized clinical trial (RCT) evidence comparing different pharmacological interventions with each other. Data regarding relative efficacy and adverse effects of each drug can inform patients, health care practitioners, and policy makers regarding optimal medication prescription to treat obesity and overweight. In this systematic review, associations of each drug with weight loss and adverse effects were compared using a direct meta-analysis and Bayesian network meta-analysis.
Methods
This systematic review is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement extension for network meta-analysis 5 and was conducted following an a priori-established protocol registered with PROSPERO (CRD42015026114). 6 Good research practices outlined in the International Society for Pharmacoeconomics and Outcomes Research report on interpreting indirect treatment comparisons and network metaanalysis for health care decision making were followed. 7 Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria for network meta-analysis were used to appraise quality of evidence. 8 
Selection Criteria
Randomized clinical trials were included in this meta-analysis if they studied any of the 5 FDA-approved weight loss drugs administered at the most effective recommended doses for at least 1 year compared with either placebo or each other in obese (BMI ≥30) or overweight (BMI ≥27) adults (aged ≥18 years), with or without weight-associated comorbidities, and reported either proportion of patients achieving at least 5% weight loss or differences in mean weight loss between different study groups. Observational studies, trials of short-term or nonapproved pharmacological agents (eg, rimonabant, sibutramine), trials comparing individual components of the approved fixed-dose combination medic ations (eg, naltrexone-bupropion, phentermine-topiramate), studies in special populations (patients with nonalcoholic fatty liver disease or polycystic ovary syndrome), and studies comparing an active agent with another nonapproved weight loss therapy (eg, metformin, statins) were excluded.
Search Strategy
The search strategy was designed and conducted by an experienced medical librarian with input from study investigators using various databases from inception to March 23, 2016. The databases included Ovid MEDLINE, EMBASE, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials. Clinical trial registries (http://www.clinicaltrials.gov and http: //www.clinicaltrialsregister.eu), conference proceedings, and published systematic reviews were screened for additional studies. Details of the search strategy and study selection procedures are shown in the eAppendix in the Supplement.
Data Abstraction and Quality Assessment
Data on study-, patient-and treatment-related characteristics were abstracted onto a standardized form by 2 authors (R.K. and A.K.C.) independently and discrepancies were resolved by consensus in consultation with a third reviewer (S.S.). Details of the data abstraction are reported in the eAppendix in the Supplement. When trials randomized patients to different dosages of the active intervention, only data for the most effective FDA-approved dosage of the medication (orlistat, 120 mg 3 times daily; lorcaserin, 10 mg twice daily; naltrexonebupropion, 32 mg/360 mg twice daily; phenterminetopiramate, 15 mg/92 mg once daily; and liraglutide, 3-mg subcutaneous injection daily) were used. [2] [3] [4] The risk of bias of individual studies was assessed in the context of the primary outcome using the Cochrane Risk of Bias assessment tool. 9 
Outcomes
All outcomes were assessed at 1 year of follow-up (52 [±4] weeks). The primary outcome was the proportion of patients achieving at least 5% weight loss from baseline, since this is the primary efficacy outcome mandated by the FDA in trials evaluating weight loss drugs and associated with clinically significant improvement in metabolic risk profile. 10, 11 Secondary weight loss outcomes were the proportion of individuals with at least 10% weight loss and change in weight from baseline. The primary adverse event outcome was rate of discontinuation of treatment due to adverse events. Serious adverse events were not consistently defined or reported. All data were abstracted using study-reported modified intention-to-treat analysis (ie, patients who received at least 1 dose of the drug and had 1 postrandomization weight assessment); imputation of missing values was performed in all studies using last observation carried forward (LOCF) in accordance with FDA guidelines regarding trials of weight loss agents. 10 
Quality of Evidence
The GRADE approach was used to rate the quality of evidence of estimates derived from network meta-analysis. 8 In this approach, direct evidence from RCTs starts at high quality and can be downgraded based on risk of bias, indirectness, imprecision, inconsistency (or heterogeneity), and/or publication bias to levels of moderate, low, and very low quality. The rating of indirect estimates starts at the lowest rating of the 2 pairwise estimates that contribute as first-order loops to the indirect estimate but can be downgraded further for imprecision or intransitivity (dissimilarity between studies in clinical or methodological characteristics). If direct and indirect estimates were similar (ie, coherent), then the higher of their ratings was assigned to the network meta-analysis estimates. assessed using the I 2 statistic, with values higher than 50% indicating substantial heterogeneity. 13 In post hoc sensitivity analyses, summary estimates were also derived using the Hartung-Knapp method to address possible type I error with the conventional DerSimonian and Laird approach. 14 Publication bias was assessed by examining funnel-plot symmetry and using the Egger regression test, with P < .05 suggesting publication bias. 15, 16 To incorporate indirect comparisons with direct comparisons, random-effects Bayesian network meta-analyses were conducted using Markov chain Monte Carlo methods in WinBUGS version 1.4.3 (MRC Biostatistics Unit) and methods described by Lu and Ades. 17, 18 The relative ranking of agents on weight loss and adverse events outcomes was presented as their surface under the cumulative ranking (SUCRA) probabilities, which represent their likelihood of being ranked best. 19 In this study, higher SUCRA scores reflect higher associated weight loss and a lower rate of adverse events. Furthermore, using ORs derived from the network meta-analysis for placebo comparisons and median placebo response rate as the assumed control risk, absolute event rates for each intervention were estimated. 20 Details of the statistical analysis and the WinBUGS code are reported in the eAppendix in the Supplement. The level of statistical significance was set at P < .05 and all statistical tests were 2-sided. Multiple sensitivity analyses were performed to assess the robustness of the findings. These were based on (1) Study selection is shown in Figure 1 . The available direct comparisons and network of trials are shown in Figure 2 and eFigure 1 in the Supplement.
Characteristics and Quality of Included Studies
The RCTs included in the network meta-analysis are summarized in Table 1 and Table 2 . Overall, these 28 trials were reported between 1998 and 2015 and included 29 018 participants (the range of size of trials was 220 to 3731 participants). The primary outcome (proportion of patients achieving at least 5% weight loss at 1 year) was reported in all studies except one, which reported only weight loss on a continuous scale.
36
The baseline characteristics of patients included in these trials are described in eTable 1 in the Supplement. The median of average age of study participants was 45.9 years (range of average age, 40.0-59.8 years) and 74% of participants were women (range, 45%-92%). The median of average BMI of patients was 36.1 (range, 32.6-42.0) and the median of average baseline weight was 100.5 kg (range, 95.3-115.8 kg). Sixteen trials were performed exclusively in patients without diabetes (or diet-controlled diabetes), whereas 8 trials were conducted in patients with diabetes treated with pharmacological therapy. Baseline patient characteristics and prognostic factors were comparably distributed in the active and comparator groups and across different trials. In all trials, participants received standard dietary and lifestyle counseling without a structured intervention; in 1 trial, all participants received intensive behavioral modification. 44 Overall, studies were considered to be at high risk of bias, with attrition rates of 30% to 45% in all trials. Overall and study-level quality assessments are summarized in eFigure 2 in the Supplement.
Direct Meta-analysis
Results of direct pairwise meta-analysis are summarized in Table 3 and eFigure 3 in the Supplement. All agents were associated with higher proportions of patients achieving at least 5% and at least 10% weight loss compared with placebo. Overall, the excess weight loss compared with placebo (ie, weighted mean difference for the drug-to-placebo comparison for the respective drug) was 2.6 kg (95% CI, 2.3-2.9 kg) with orlistat, 3.2 kg (95% CI, 3.0-3.6 kg) with lorcaserin, 5.0 kg (95% CI, 4.4-5.5 kg) with naltrexone-bupropion, 8.8 kg (95% CI, 8.0-9.6 kg) with phentermine-topiramate, and 5.2 kg (95% CI, 4.9-5.6 kg) with liraglutide. All agents were more frequently discontinued because of adverse events than placebo (Table 3 ). Significant heterogeneity was observed for most comparisons, but the difference was primarily in the magnitude of effect size, not in the direction. In the only head-to-head comparison, liraglutide resulted in greater weight loss compared with orlistat, with no difference in adverse events. 49 In post hoc sensitivity analysis using the Hartung-Knapp method, all results were consistent (eTable 2 in the Supplement).
Network Meta-analysis-Weight Loss Outcomes Figure 3 ). All agents were also associated with higher odds of at least 10% weight loss from baseline compared with placebo (eTable 3 in the Supplement). Placebo was associated with a 23% median rate of achieving at least 5% weight loss while phenterminetopiramate was associated with achieving at least 5% weight loss in an estimated 75% of participants, liraglutide in an estimated 63%, naltrexone-bupropion in an estimated 55%, lorcaserin in an estimated 49%, and orlistat in an estimated 44% (eTable 4 in the Supplement). Similarly, with a 9% median rate of achieving at least 10% weight loss in placebo-treated patients, phentermine-topiramate was associated with achieving at least 10% weight loss in an estimated 54% of participants, liraglutide in an estimated 34%, naltrexonebupropion in an estimated 30%, lorcaserin in an estimated 25%, and orlistat in an estimated 20%. Baseline calculated using World Health Organization equations; 30% of energy from fat, 20% from protein, and 50% from carbohydrate. 
Research Original Investigation
Weight Loss and Adverse Events With Pharmacological Therapy for Obesity
Weight Loss in Excess of Placebo
In network meta-analysis, all active agents were associated with significant excess weight loss vs placebo at 1 year-orlistat, Network meta-analysis also suggested that phenterminetopiramate, 15 mg/92 mg once daily, was associated with significant excess weight loss compared with all active agents (change vs orlistat, 6.2 kg; vs lorcaserin, 5.6 kg; vs naltrexone-bupropion, 3.9 kg; and vs liraglutide, 3.5 kg) (eTable 3 in the Supplement).
Sensitivity Analysis
Results from multiple sensitivity analyses are reported in eTables 5-8 in the Supplement. Overall, the results were similar to the main analysis for the primary outcome in sensitivity analyses based on (1) alternative statistical model (frequentist approach using a random-effects inconsistency model, worst-case scenario, complete-case analysis); (2) restricting to only studies in adults without diabetes; and (3) replacing trials of high-dose phentermine-topiramate with standard-dose phentermine-topiramate (7.5 mg/46 mg once daily).
Network Meta-analysis-Adverse Event Outcome
In network meta-analysis, compared with placebo, all active agents had 1.3 to 2.9 higher odds of being associated with discontinuation due to adverse events ( Figure 3) . Compared with placebo, lorcaserin was associated with the lowest odds of being discontinued because of adverse events (OR, Figure 4 and eTable 4 in the Supplement). Details of the most commonly observed adverse events and reported reasons for discontinuation are shown in eTable 9 in the Supplement.
Publication Bias and Network Coherence
There was no evidence of publication bias, either qualitatively based on funnel-plot asymmetry (eFigure 4 in the Supplement) or quantitatively (Egger regression test, P > .05 for all comparisons), although the number of studies included in each comparison was very small. There were no significant differences between direct and indirect estimates in the only closed loop that allowed assessment of network coherence (placebo-orlistat-liraglutide). Visual inspection of trace plots and evaluation of the Monte Carlo error and the BrooksGelman-Rubin statistic suggested adequacy of burn-in and convergence. 50 Values of the total residual deviance suggested good model fit.
Quality of Evidence
Given high attrition rates for all trials (30%-45%), evidence was downgraded for risk of bias. Although several comparisons had statistically significant heterogeneity, the difference was primarily in the magnitude of effect size, not in the direction of effect, and hence, evidence was not downgraded for inconsistency. On applying GRADE to findings from the network meta-analysis combining direct and indirect evidence, there was moderate-quality evidence for all agents being associated with higher odds of achieving at least 5% weight loss compared with placebo. In comparing different drugs against each other, there was moderatequality evidence for phentermine-topiramate being associated with higher odds of achieving weight loss compared with all other drugs. There was also moderate-quality evidence for liraglutide being associated with higher odds of achieving weight loss compared with orlistat and lorcaserin and low-quality evidence for liraglutide being associated with higher odds of achieving weight loss compared with naltrexone-bupropion (which was downgraded for imprecision and risk of bias) (eTable 10 in the Supplement). Surface under the cumulative rankings (SUCRAs) between 0 and 1 represent the probability of being ranked highest. For the weight loss outcomes, higher score corresponds to higher proportion achieving at least 5% weight loss with a particular therapy. For the adverse event outcome, higher scores reflect lower probability of discontinuation due to adverse events. The median ranks on both weight loss and adverse event rates (rank 1 through 6 on each scale) are tabulated along with their corresponding 95% credible intervals (95% CrIs).
Discussion
In this systematic review and network meta-analysis, direct and indirect evidence from 28 RCTs in 29 018 overweight and obese patients was combined to compare the association of each drug with relative weight loss and adverse events. The study has several key findings. First, with at least 1 year of treatment, orlistat, lorcaserin, naltrexone-bupropion, phenterminetopiramate, and liraglutide are all associated with higher odds of achieving weight loss compared with placebo, with moderate confidence in estimates. Second, phenterminetopiramate was associated with higher odds of achieving weight loss of at least 5% and weight loss of at least 10% compared with all other active agents, with moderate confidence in estimates, and there was no difference in the odds of adverse event-related drug discontinuation among phenterminetopiramate, liraglutide, and naltrexone-bupropion. Third, liraglutide was associated with higher odds of weight loss of at least 5% and weight loss of at least 10% compared with orlistat, lorcaserin, and naltrexone-bupropion, with low to moderate confidence in estimates, but was associated with higher odds of discontinuation due to adverse events. The US Preventive Services Task Force recommends referral of all obese adults to intensive, multicomponent interventions including behavioral interventions, pharmacological therapies, and surgical weight loss procedures. 51 The Endocrine Society also suggests the use of approved weight loss medications for longterm weight maintenance, to ameliorate comorbidities, and to enhance adherence to behavior changes. 52 However, there are no current recommendations to guide clinicians regarding choice of individual drugs. The present study found moderate-quality evidence for phentermine-topiramate being associated with higher odds of achieving predefined thresholds of clinically meaningful weight loss compared with other currently approved agents. The odds of discontinuation of therapy due to medication-related adverse events was not different for phentermine-topiramate, liraglutide, and naltrexone-bupropion. While lorcaserin and orlistat were associated with lower rates of adverse events, they were also associated with lower rates of achieving all weight loss outcomes. Besides weight loss, treatment decisions may also be driven by coexisting medical conditions, which may either favor or preclude the use of specific agents. 2 For example, liraglutide may be a more appropriate agent in people with diabetes because of its glucose-lowering effects. 47 Conversely, naltrexone-bupropion in patients with chronic opiate or alcohol dependence may be associated with neuropsychiatric complications. 2 Ultimately, given the differences in safety, efficacy, and response to therapy, the ideal approach to weight loss should be highly individualized, identifying appropriate candidates for pharmacotherapy, behavioral interventions, and surgical interventions. 53 Historically, concerns regarding the long-term safety profile of pharmacotherapy for weight loss have limited their clinical use, particularly among medications with significant adrenergic actions (eg, sibutramine) or central appetite-suppressing actions (eg, rimonabant). 54 Shortterm clinical trials may not provide comprehensive information on the long-term safety of these agents, and prospective postmarketing surveillance studies are warranted. This study has limitations. First, there was a paucity of direct comparative studies. Four of the 5 studied agents received approval from the FDA within the last 3 years, and because there is no established standard weight loss agent against which a new agent needs to be compared for approval, there is a paucity of head-to-head trials. Second, the biggest threat to validity of the results of any meta-analysis is conceptual heterogeneity-ie, considerable differences among trials in patient characteristics, studied interventions, cointerventions/background therapy, outcome assessment, or study design-which can limit the comparability of trials. Strategies to limit the effect of conceptual heterogeneity included strict inclusion and exclusion criteria and the use of multiple sensitivity analyses to assess the robustness of the results. Cointerventions in the studies, including diet and exercise recommendations and behavioral modification, were similar, although rigor of implementation and adherence by trial participants was not routinely measured, and their association with the relative efficacy of active interventions is unclear. Third, ranking probabilities may be affected by unequal numbers of trials per comparison, sample size of individual studies, network configuration, and effect sizes among treatments and should be interpreted with caution. Finally, all included trials had a high rate of attrition. Although statistical tools allowed interpretation of these data (using an LOCF imputation as suggested by the FDA guidelines), there are unaddressed concerns regarding the longterm effect of weight loss agents in a clinical setting.
Conclusions
Among overweight or obese adults, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide, compared with placebo, were each associated with achieving at least 5% weight loss at 52 weeks. Phenterminetopiramate and liraglutide were associated with the highest odds of achieving at least 5% weight loss.
